Nasopharyngeal carcinoma screening: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Bot: Removing from Primary care)
 
(13 intermediate revisions by 4 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing.
{{Nasopharyngeal carcinoma}}
{{Nasopharyngeal carcinoma}}
{{CMG}} {{AE}}{{Homa}}{{Faizan}}
==Overview==
[[Screening (medicine)|Screening]] for nasopharyngeal carcinoma only is done in [[Endemic (epidemiology)|endemic]] areas. Different methods, such as measurement the [[Titer|titre]] of  different types of [[antibodies]] against [[Epstein Barr virus|EBV]] and [[plasma]] [[Epstein Barr virus|EBV]] [[DNA]], and [[endoscopic]] [[examination]] of [[nasopharynx]] can be used for [[screening]].
==Screening==
[[Screening (medicine)|Screening]] for nasopharyngeal carcinoma only is done in [[Endemic (epidemiology)|endemic]] areas, the [[Screening (medicine)|screening]] methods which can be used are:<ref name="AltunFandi1995">{{cite journal|last1=Altun|first1=M.|last2=Fandi|first2=A.|last3=Dupuis|first3=O.|last4=Cvitkovic|first4=E.|last5=Krajina|first5=Z.|last6=Eschwege|first6=F.|title=Undifferentiated nasopharyngeal cancer (UCNT): Current diagnostic and therapeutic aspects|journal=International Journal of Radiation Oncology*Biology*Physics|volume=32|issue=3|year=1995|pages=859–877|issn=03603016|doi=10.1016/0360-3016(95)00516-2}}</ref><ref name="WangTwu2010">{{cite journal|last1=Wang|first1=W.-Y.|last2=Twu|first2=C.-W.|last3=Chen|first3=H.-H.|last4=Jan|first4=J.-S.|last5=Jiang|first5=R.-S.|last6=Chao|first6=J. Y.C.|last7=Liang|first7=K.-L.|last8=Chen|first8=K.-W.|last9=Wu|first9=C.-T.|last10=Lin|first10=J.-C.|title=Plasma EBV DNA Clearance Rate as a Novel Prognostic Marker for Metastatic/Recurrent Nasopharyngeal Carcinoma|journal=Clinical Cancer Research|volume=16|issue=3|year=2010|pages=1016–1024|issn=1078-0432|doi=10.1158/1078-0432.CCR-09-2796}}</ref><ref>{{Cite journal
| author = [[Y. Zeng]], [[L. G. Zhang]], [[Y. C. Wu]], [[Y. S. Huang]], [[N. Q. Huang]], [[J. Y. Li]], [[Y. B. Wang]], [[M. K. Jiang]], [[Z. Fang]] & [[N. N. Meng]]
| title = Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China
| journal = [[International journal of cancer]]
| volume = 36
| issue = 5
| pages = 545–547
| year = 1985
| month = November
| pmid = 4055129
}}</ref><ref>{{Cite journal
| author = [[Y. S. Zong]], [[J. S. Sham]], [[M. H. Ng]], [[X. T. Ou]], [[Y. Q. Guo]], [[S. A. Zheng]], [[J. S. Liang]] & [[H. Qiu]]
| title = Immunoglobulin A against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma
| journal = [[Cancer]]
| volume = 69
| issue = 1
| pages = 3–7
| year = 1992
| month = January
| pmid = 1309307
}}</ref><ref>{{Cite journal
| author = [[Wei-min Cheng]], [[Kwok Hung Chan]], [[Hong-lin Chen]], [[Rui-xian Luo]], [[S. Park Ng]], [[Winsie Luk]], [[Bo-jian Zheng]], [[Ming-fang Ji]], [[Jin-sheng Liang]], [[Jonathan S. T. Sham]], [[De-Kun Wang]], [[Yong-sheng Zong]] & [[Mun Hon Ng]]
| title = Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum
| journal = [[International journal of cancer]]
| volume = 97
| issue = 4
| pages = 489–492
| year = 2002
| month = February
| pmid = 11802211
}}</ref><ref name="ChienChen2001">{{cite journal|last1=Chien|first1=Yin-Chu|last2=Chen|first2=Jen-Yang|last3=Liu|first3=Mei-Ying|last4=Yang|first4=Hwai-I|last5=Hsu|first5=Mow-Ming|last6=Chen|first6=Chien-Jen|last7=Yang|first7=Czau-Siung|title=Serologic Markers of Epstein–Barr Virus Infection and Nasopharyngeal Carcinoma in Taiwanese Men|journal=New England Journal of Medicine|volume=345|issue=26|year=2001|pages=1877–1882|issn=0028-4793|doi=10.1056/NEJMoa011610}}</ref><ref name="YuHsu2011">{{cite journal|last1=Yu|first1=K. J.|last2=Hsu|first2=W.-L.|last3=Pfeiffer|first3=R. M.|last4=Chiang|first4=C.-J.|last5=Wang|first5=C.-P.|last6=Lou|first6=P.-J.|last7=Cheng|first7=Y.-J.|last8=Gravitt|first8=P.|last9=Diehl|first9=S. R.|last10=Goldstein|first10=A. M.|last11=Chen|first11=C.-J.|last12=Hildesheim|first12=A.|title=Prognostic Utility of Anti-EBV Antibody Testing for Defining NPC Risk among Individuals from High-Risk NPC Families|journal=Clinical Cancer Research|volume=17|issue=7|year=2011|pages=1906–1914|issn=1078-0432|doi=10.1158/1078-0432.CCR-10-1681}}</ref><ref name="Leung2004">{{cite journal|last1=Leung|first1=S.-f.|title=Improved Accuracy of Detection of Nasopharyngeal Carcinoma by Combined Application of Circulating Epstein-Barr Virus DNA and Anti-Epstein-Barr Viral Capsid Antigen IgA Antibody|journal=Clinical Chemistry|volume=50|issue=2|year=2004|pages=339–345|issn=0009-9147|doi=10.1373/clinchem.2003.022426}}</ref>
*Measuring the [[Titer|titre]] levels of:
**[[Antibody]] against [[Epstein Barr virus|EBV]] immunoglobulin A capsod antigen (IgA VCA)
**[[Antibody]] against [[Epstein Barr virus|EBV]] immunoglobulin A early antigen (IgA EA)
**[[Antibody]] against [[Epstein Barr virus|EBV]] nuclear antigen 1 (EBNA1-IgA)
**[[Antibody]] against [[EBV]]-specific DNase
**[[Plasma]] EBV DNA by real-time [[Polymerase chain reaction|PCR]]
*[[Endoscopy|Endoscopic]] [[examination]] of [[nasopharynx]]
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
Line 8: Line 52:
{{WikiDoc Sources}}
{{WikiDoc Sources}}


[[Category:Disease]]
[[Category:Up-To-Date]]
[[Category:Needs content]]
[[Category:Medicine]]
[[Category:Types of cancer]]
[[Category:Oncology]]
[[Category:Oncology]]
[[Category:Otolaryngology]]

Latest revision as of 22:54, 29 July 2020

Nasopharyngeal carcinoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Nasopharyngeal carcinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Nasopharyngeal carcinoma screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Nasopharyngeal carcinoma screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Nasopharyngeal carcinoma screening

CDC on Nasopharyngeal carcinoma screening

Nasopharyngeal carcinoma screening in the news

Blogs on Nasopharyngeal carcinoma screening

Directions to Hospitals Treating Nasopharyngeal carcinoma

Risk calculators and risk factors for Nasopharyngeal carcinoma screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]Faizan Sheraz, M.D. [3]

Overview

Screening for nasopharyngeal carcinoma only is done in endemic areas. Different methods, such as measurement the titre of different types of antibodies against EBV and plasma EBV DNA, and endoscopic examination of nasopharynx can be used for screening.

Screening

Screening for nasopharyngeal carcinoma only is done in endemic areas, the screening methods which can be used are:[1][2][3][4][5][6][7][8]

References

  1. Altun, M.; Fandi, A.; Dupuis, O.; Cvitkovic, E.; Krajina, Z.; Eschwege, F. (1995). "Undifferentiated nasopharyngeal cancer (UCNT): Current diagnostic and therapeutic aspects". International Journal of Radiation Oncology*Biology*Physics. 32 (3): 859–877. doi:10.1016/0360-3016(95)00516-2. ISSN 0360-3016.
  2. Wang, W.-Y.; Twu, C.-W.; Chen, H.-H.; Jan, J.-S.; Jiang, R.-S.; Chao, J. Y.C.; Liang, K.-L.; Chen, K.-W.; Wu, C.-T.; Lin, J.-C. (2010). "Plasma EBV DNA Clearance Rate as a Novel Prognostic Marker for Metastatic/Recurrent Nasopharyngeal Carcinoma". Clinical Cancer Research. 16 (3): 1016–1024. doi:10.1158/1078-0432.CCR-09-2796. ISSN 1078-0432.
  3. Y. Zeng, L. G. Zhang, Y. C. Wu, Y. S. Huang, N. Q. Huang, J. Y. Li, Y. B. Wang, M. K. Jiang, Z. Fang & N. N. Meng (1985). "Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China". International journal of cancer. 36 (5): 545–547. PMID 4055129. Unknown parameter |month= ignored (help)
  4. Y. S. Zong, J. S. Sham, M. H. Ng, X. T. Ou, Y. Q. Guo, S. A. Zheng, J. S. Liang & H. Qiu (1992). "Immunoglobulin A against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma". Cancer. 69 (1): 3–7. PMID 1309307. Unknown parameter |month= ignored (help)
  5. Wei-min Cheng, Kwok Hung Chan, Hong-lin Chen, Rui-xian Luo, S. Park Ng, Winsie Luk, Bo-jian Zheng, Ming-fang Ji, Jin-sheng Liang, Jonathan S. T. Sham, De-Kun Wang, Yong-sheng Zong & Mun Hon Ng (2002). "Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum". International journal of cancer. 97 (4): 489–492. PMID 11802211. Unknown parameter |month= ignored (help)
  6. Chien, Yin-Chu; Chen, Jen-Yang; Liu, Mei-Ying; Yang, Hwai-I; Hsu, Mow-Ming; Chen, Chien-Jen; Yang, Czau-Siung (2001). "Serologic Markers of Epstein–Barr Virus Infection and Nasopharyngeal Carcinoma in Taiwanese Men". New England Journal of Medicine. 345 (26): 1877–1882. doi:10.1056/NEJMoa011610. ISSN 0028-4793.
  7. Yu, K. J.; Hsu, W.-L.; Pfeiffer, R. M.; Chiang, C.-J.; Wang, C.-P.; Lou, P.-J.; Cheng, Y.-J.; Gravitt, P.; Diehl, S. R.; Goldstein, A. M.; Chen, C.-J.; Hildesheim, A. (2011). "Prognostic Utility of Anti-EBV Antibody Testing for Defining NPC Risk among Individuals from High-Risk NPC Families". Clinical Cancer Research. 17 (7): 1906–1914. doi:10.1158/1078-0432.CCR-10-1681. ISSN 1078-0432.
  8. Leung, S.-f. (2004). "Improved Accuracy of Detection of Nasopharyngeal Carcinoma by Combined Application of Circulating Epstein-Barr Virus DNA and Anti-Epstein-Barr Viral Capsid Antigen IgA Antibody". Clinical Chemistry. 50 (2): 339–345. doi:10.1373/clinchem.2003.022426. ISSN 0009-9147.


Template:WikiDoc Sources